Convert your Cagrilintide dose
Vial
Result
Converted amount0.25 mg
Dose mass250 mcg
Concentration2,500 mcg/mL
Draw volume0.1 mL
U-100 syringe10 units
Reported study ranges
| Purpose | Route | Reported range | Frequency |
|---|---|---|---|
| Obesity treatment (clinical trial protocol) | subcutaneous | 0.25–2.4 mg | once weekly |
Ranges are reported from the literature for research context only. They are not a protocol and not a recommendation.
Concentration by vial and diluent
| Vial | 1 mL diluent | 2 mL diluent | 3 mL diluent |
|---|---|---|---|
| 2 mg | 2,000 mcg/mL | 1,000 mcg/mL | 667 mcg/mL |
| 5 mg | 5,000 mcg/mL | 2,500 mcg/mL | 1,667 mcg/mL |
| 10 mg | 10,000 mcg/mL | 5,000 mcg/mL | 3,333 mcg/mL |
Concentration is vial mass divided by diluent volume. Reconstitution volume changes what you draw, never the dose itself.
What to draw for 250 mcg
| Vial | Diluent | Draw volume | U-100 units | Doses per vial |
|---|---|---|---|---|
| 2 mg | 1 mL | 0.125 mL | 12.5 units | 8 |
| 2 mg | 2 mL | 0.25 mL | 25 units | 8 |
| 2 mg | 3 mL | 0.375 mL | 37.5 units | 8 |
| 5 mg | 1 mL | 0.05 mL | 5 units | 20 |
| 5 mg | 2 mL | 0.1 mL | 10 units | 20 |
| 5 mg | 3 mL | 0.15 mL | 15 units | 20 |
| 10 mg | 1 mL | 0.025 mL | 2.5 units | 40 |
| 10 mg | 2 mL | 0.05 mL | 5 units | 40 |
| 10 mg | 3 mL | 0.075 mL | 7.5 units | 40 |
Calculated for the low end of the reported Obesity treatment (clinical trial protocol) range. Change the dose in the calculator above for any other amount.
Cagrilintide at a glance
~159–195 hours (~7–8 days)
Half-life
4,409 Da
Molecular weight
subcutaneous
Routes
research only
Legal status